Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin

Wei Ching Chen, Hui Ping Hsu, Chung Yen Li, Ya Ju Yang, Yu Hsuan Hung, Chien Yu Cho, Chih Yang Wang, Tzu Yang Weng, Ming Derg Lai

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cancer stem cell (CSC) markers have been identified for CSC isolation and proposed as therapeutic targets in various types of cancers. CD90, one of the characterized markers in liver and gastric cancer, is shown to promote cancer formation. However, the underexpression level of CD90 in ovarian cancer cells and the evidence supporting the cellular mechanism have not been investigated. In the present study, we found that the DNA copy number of CD90 is correlated with mRNA expression in ovarian cancer tissue and the ovarian cancer patients with higher CD90 have good prognosis compared to the patients with lower CD90. Although the expression of CD90 in human ovarian cancer SKOV3 cells enhances the cell proliferation by MTT and anchorage-dependent growth assay, CD90 inhibits the anchorage-independent growth ability in vitro and tumor formation in vivo. CD90 overexpression suppresses the sphere-forming ability and ALDH activity and enhances the cell apoptosis, indicating that CD90 may reduce the cell growth by the properties of CSC and anoikis. Furthermore, CD90 reduces the expression of other CSC markers, including CD133 and CD24. The inhibition of CD133 is attenuated by the mutant CD90, which is replaced with RLE domain into RLD domain. Importantly, the CD90-regulated inhibition of CD133 expression, anchorage-independent growth and signal transduction of mTOR and AMPK are restored by the β3 integrin shRNA. Our results provide evidence that CD90 mediates the antitumor formation by interacting with β3 integrin, which provides new insight that can potentially be applied in the development of therapeutic strategies in ovarian cancer.

Original languageEnglish
Pages (from-to)1881-1889
Number of pages9
JournalInternational Journal of Oncology
Volume49
Issue number5
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

Xenograft Model Antitumor Assays
Thy-1 Antigens
Anoikis
Cultured Tumor Cells
Integrin beta3
Inbred NOD Mouse
AMP-Activated Protein Kinases
SCID Mice
Neoplastic Stem Cells
Reverse Transcriptase Polymerase Chain Reaction
Cell Adhesion
Integrins
Ovarian Neoplasms
Cell Movement
Real-Time Polymerase Chain Reaction
Cell Cycle
Flow Cytometry
Western Blotting
Cell Proliferation
Apoptosis

Keywords

  • AMPK
  • Cancer stem cell marker
  • CD133
  • Integrin
  • MTOR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chen, W. C., Hsu, H. P., Li, C. Y., Yang, Y. J., Hung, Y. H., Cho, C. Y., ... Lai, M. D. (2016). Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin. International Journal of Oncology, 49(5), 1881-1889. https://doi.org/10.3892/ijo.2016.3691

Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin. / Chen, Wei Ching; Hsu, Hui Ping; Li, Chung Yen; Yang, Ya Ju; Hung, Yu Hsuan; Cho, Chien Yu; Wang, Chih Yang; Weng, Tzu Yang; Lai, Ming Derg.

In: International Journal of Oncology, Vol. 49, No. 5, 01.11.2016, p. 1881-1889.

Research output: Contribution to journalArticle

Chen, WC, Hsu, HP, Li, CY, Yang, YJ, Hung, YH, Cho, CY, Wang, CY, Weng, TY & Lai, MD 2016, 'Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin', International Journal of Oncology, vol. 49, no. 5, pp. 1881-1889. https://doi.org/10.3892/ijo.2016.3691
Chen, Wei Ching ; Hsu, Hui Ping ; Li, Chung Yen ; Yang, Ya Ju ; Hung, Yu Hsuan ; Cho, Chien Yu ; Wang, Chih Yang ; Weng, Tzu Yang ; Lai, Ming Derg. / Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin. In: International Journal of Oncology. 2016 ; Vol. 49, No. 5. pp. 1881-1889.
@article{81eba662f9f6420da157aad7172d5b34,
title = "Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin",
abstract = "Cancer stem cell (CSC) markers have been identified for CSC isolation and proposed as therapeutic targets in various types of cancers. CD90, one of the characterized markers in liver and gastric cancer, is shown to promote cancer formation. However, the underexpression level of CD90 in ovarian cancer cells and the evidence supporting the cellular mechanism have not been investigated. In the present study, we found that the DNA copy number of CD90 is correlated with mRNA expression in ovarian cancer tissue and the ovarian cancer patients with higher CD90 have good prognosis compared to the patients with lower CD90. Although the expression of CD90 in human ovarian cancer SKOV3 cells enhances the cell proliferation by MTT and anchorage-dependent growth assay, CD90 inhibits the anchorage-independent growth ability in vitro and tumor formation in vivo. CD90 overexpression suppresses the sphere-forming ability and ALDH activity and enhances the cell apoptosis, indicating that CD90 may reduce the cell growth by the properties of CSC and anoikis. Furthermore, CD90 reduces the expression of other CSC markers, including CD133 and CD24. The inhibition of CD133 is attenuated by the mutant CD90, which is replaced with RLE domain into RLD domain. Importantly, the CD90-regulated inhibition of CD133 expression, anchorage-independent growth and signal transduction of mTOR and AMPK are restored by the β3 integrin shRNA. Our results provide evidence that CD90 mediates the antitumor formation by interacting with β3 integrin, which provides new insight that can potentially be applied in the development of therapeutic strategies in ovarian cancer.",
keywords = "AMPK, Cancer stem cell marker, CD133, Integrin, MTOR",
author = "Chen, {Wei Ching} and Hsu, {Hui Ping} and Li, {Chung Yen} and Yang, {Ya Ju} and Hung, {Yu Hsuan} and Cho, {Chien Yu} and Wang, {Chih Yang} and Weng, {Tzu Yang} and Lai, {Ming Derg}",
year = "2016",
month = "11",
day = "1",
doi = "10.3892/ijo.2016.3691",
language = "English",
volume = "49",
pages = "1881--1889",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin

AU - Chen, Wei Ching

AU - Hsu, Hui Ping

AU - Li, Chung Yen

AU - Yang, Ya Ju

AU - Hung, Yu Hsuan

AU - Cho, Chien Yu

AU - Wang, Chih Yang

AU - Weng, Tzu Yang

AU - Lai, Ming Derg

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Cancer stem cell (CSC) markers have been identified for CSC isolation and proposed as therapeutic targets in various types of cancers. CD90, one of the characterized markers in liver and gastric cancer, is shown to promote cancer formation. However, the underexpression level of CD90 in ovarian cancer cells and the evidence supporting the cellular mechanism have not been investigated. In the present study, we found that the DNA copy number of CD90 is correlated with mRNA expression in ovarian cancer tissue and the ovarian cancer patients with higher CD90 have good prognosis compared to the patients with lower CD90. Although the expression of CD90 in human ovarian cancer SKOV3 cells enhances the cell proliferation by MTT and anchorage-dependent growth assay, CD90 inhibits the anchorage-independent growth ability in vitro and tumor formation in vivo. CD90 overexpression suppresses the sphere-forming ability and ALDH activity and enhances the cell apoptosis, indicating that CD90 may reduce the cell growth by the properties of CSC and anoikis. Furthermore, CD90 reduces the expression of other CSC markers, including CD133 and CD24. The inhibition of CD133 is attenuated by the mutant CD90, which is replaced with RLE domain into RLD domain. Importantly, the CD90-regulated inhibition of CD133 expression, anchorage-independent growth and signal transduction of mTOR and AMPK are restored by the β3 integrin shRNA. Our results provide evidence that CD90 mediates the antitumor formation by interacting with β3 integrin, which provides new insight that can potentially be applied in the development of therapeutic strategies in ovarian cancer.

AB - Cancer stem cell (CSC) markers have been identified for CSC isolation and proposed as therapeutic targets in various types of cancers. CD90, one of the characterized markers in liver and gastric cancer, is shown to promote cancer formation. However, the underexpression level of CD90 in ovarian cancer cells and the evidence supporting the cellular mechanism have not been investigated. In the present study, we found that the DNA copy number of CD90 is correlated with mRNA expression in ovarian cancer tissue and the ovarian cancer patients with higher CD90 have good prognosis compared to the patients with lower CD90. Although the expression of CD90 in human ovarian cancer SKOV3 cells enhances the cell proliferation by MTT and anchorage-dependent growth assay, CD90 inhibits the anchorage-independent growth ability in vitro and tumor formation in vivo. CD90 overexpression suppresses the sphere-forming ability and ALDH activity and enhances the cell apoptosis, indicating that CD90 may reduce the cell growth by the properties of CSC and anoikis. Furthermore, CD90 reduces the expression of other CSC markers, including CD133 and CD24. The inhibition of CD133 is attenuated by the mutant CD90, which is replaced with RLE domain into RLD domain. Importantly, the CD90-regulated inhibition of CD133 expression, anchorage-independent growth and signal transduction of mTOR and AMPK are restored by the β3 integrin shRNA. Our results provide evidence that CD90 mediates the antitumor formation by interacting with β3 integrin, which provides new insight that can potentially be applied in the development of therapeutic strategies in ovarian cancer.

KW - AMPK

KW - Cancer stem cell marker

KW - CD133

KW - Integrin

KW - MTOR

UR - http://www.scopus.com/inward/record.url?scp=84992653697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992653697&partnerID=8YFLogxK

U2 - 10.3892/ijo.2016.3691

DO - 10.3892/ijo.2016.3691

M3 - Article

C2 - 27633757

AN - SCOPUS:84992653697

VL - 49

SP - 1881

EP - 1889

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -